ERK

Extracellular signal regulated kinases

ERK

ERK Isoform Specific Products:

ERK Isoform Comparison

ERK Related Products (442)
Antibodies (22)
ERK Isoform Comparison

By Effects:	Control (1) Inhibitors (287) Agonists (5) Degrader (1) Activators (92) Modulators (6) Chemical (1) Inducers (9)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-N0371

Pachymic acid	Inhibitor	99.94%
Pachymic acid is a lanostrane-type triterpenoid from P. cocos. Pachymic acid inhibits Akt and ERK signaling pathways.

HY-W008947

SEW2871	Activator	99.53%
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC₅₀ of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses.

HY-113556

Sappanone A	Inhibitor	99.58%
Sappanone A is an orally active homoisoflavone found in sappan L. Sappanone A is a PDE4 and NF-κB inhibitor with anti-inflammatory and antioxidant effect. Sappanone A induces HO-1 expression through activation of Nrf2 pathway. Sappanone A also inhibits RANKL-induced osteoclastogenesis. Sappanone A has great potential in the research of inflammation-related and cardiovascular .

HY-B2123

Lactose	Inhibitor	≥98.0%
Lactose is a β-galactoside consisting of galactose and glucose residues，the main carbohydrate in mammalian breast milk. Lactose，a macronutrient and an inducer of host innate immune responses，possesses immune modulatory functions.

HY-N7264

7α-Hydroxycholesterol		99.99%
7α-Hydroxycholesterol is a cholesterol oxide and can serve as a biomarker for oxidative stress and lipid peroxidation. 7α-Hydroxycholesterol has cytotoxic and pro-inflammatory activities. 7α-Hydroxycholesterol can also inhibit sterol synthesis and reduce the activity of HMG-CoA reductase. 7α-Hydroxycholesterol can be used in the research of diseases such as diabetes and atherosclerosis.

HY-12056

BIX02189	Inhibitor	99.99%
BIX02189 is a potent and selective MEK5 inhibitor with an IC₅₀ of 1.5 nM. BIX02189 also inhibits ERK5 catalytic activity with an IC₅₀ of 59 nM.

HY-104047

LM22B-10	Activator	99.92%
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.

HY-B0185A

Lidocaine hydrochloride	Inhibitor	99.96%
Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor.

HY-156002

LUNA18	Inhibitor	99.26%
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer.

HY-N0498

Nitidine chloride	Inhibitor	99.75%
Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK and c-Src/FAK associated signaling pathway, also has anti-inflammatory activity. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway.

HY-B0444

Maprotiline hydrochloride		99.98%
Maprotiline hydrochloride is a highly selective noradrenergic reuptake inhibitor that has strong antidepressant, antitumor and neuropathic pain-relieving effects with oral activity. Maprotiline hydrochloride induces cancer cell apoptosis by targeting the ERK signaling pathway and CRABP1.

HY-111407

MK-8353	Inhibitor	98.13%
MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC₅₀s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.

HY-14443

XMD8-92	Inhibitor	99.67%
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity.

HY-119272

EF24	Inhibitor	99.34%
EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI₅₀ values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.

HY-113772

Inflachromene	Inhibitor	99.88%
Inflachromene, a microglial inhibitor, binds to HMGB1 and HMGB2 and exerts anti-inflammatory effects. Inflachromene effectively downregulates proinflammatory functions of HMGB and reduces neuronal damage. Inflachromene can be used for the research of neuroinflammatory disorders.

HY-W004283

Pentadecanoic acid	Inhibitor	≥98.0%
Pentadecylic acid is a saturated fatty acid with a 15-carbon backbone.

HY-15816A

Ulixertinib hydrochloride	Inhibitor	99.88%
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.

HY-W011727A

Pyridoxal 5'-phosphate monohydrate	Activator	≥98.0%
Pyridoxal 5'-phosphate monohydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate monohydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′‐phosphate (PMP).

HY-17015

Peramivir trihydrate		98.30%
Peramivir trihydrate (RWJ-270201 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC₅₀ values ranging from 0.9 to 4.3 nM for nine NA subtypes.

HY-14178

VX-11e	Inhibitor	99.17%
VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with K_i < 2 nM.

Yoda 1		ERK1	ERK2			99.98%
PD98059		ERK1	ERK2			99.96%
SCH772984		ERK1, IC₅₀: 4 nM	ERK2, IC₅₀: 1 nM			99.83%
Tauroursodeoxycholate	ERK					99.93%
TBHQ	ERK					99.89%
TERT activator-1		ERK1	ERK2			99.50%
β-Glycerophosphate disodium salt pentahydrate		ERK1	ERK2			99.81%
Ulixertinib			ERK2, IC₅₀: 0.3 nM (at K_M ATP (60 μM))			99.95%
Honokiol		ERK1	ERK2			99.90%
Astragaloside IV		ERK1	ERK2			99.93%
C16-PAF	ERK					99.85%
L-Cysteine		ERK1	ERK2
Tauroursodeoxycholate sodium	ERK					98.40%
Temuterkib		ERK1, IC₅₀: 5 nM	ERK2, IC₅₀: 5 nM			99.94%
Piperlongumine		ERK1	ERK2			99.87%
Ravoxertinib		ERK1, IC₅₀: 6.1 nM	ERK2, IC₅₀: 3.1 nM			99.75%
β-Glycerophosphate disodium salt hydrate		ERK1	ERK2			≥98.0%
Lidocaine	ERK					99.96%
trans-Zeatin	ERK					99.83%
Gamma-Linolenic acid		ERK1	ERK2			99.80%
Lysophosphatidylcholines		ERK1	ERK2			≥99.0%
Fucoxanthin			ERK2			98.99%
FR 180204		ERK1, Ki: 0.31 μM ERK1, IC₅₀: 0.51 μM	ERK2, Ki: 0.14 μM ERK2, IC₅₀: 0.33 μM			99.65%
ASN007		ERK1	ERK2			99.70%
6-OAU	ERK					99.91%
Pachymic acid	ERK					99.94%
BIX02189				ERK5, IC₅₀: 59 nM		99.99%
LM22B-10	ERK					99.92%
Lidocaine hydrochloride	ERK					99.96%
MK-8353		ERK1, IC₅₀: 23 nM	ERK2, IC₅₀: 8.8 nM			98.13%
XMD8-92				BMK1, Kd: 80 nM		99.67%
VX-11e			ERK2, Ki: 2 nM			99.17%
Peiminine		ERK1	ERK2			99.94%
AG126			ERK2			≥98.0%
Peramivir		ERK1	ERK2			99.32%
AX-15836				ERK5, IC₅₀: 8 nM		99.68%
ASTX029		ERK1	ERK2			99.86%
Broussonin E	ERK					98.18%
Pluripotin		ERK1, Kd: 98 nM				98.86%
CHPG sodium salt	ERK					99.25%
ERK1/2 inhibitor 1			ERK2, IC₅₀: 3.0 nM			99.79%
Cafestol			ERK2			99.91%
H-Ile-Lys-Val-Ala-Val-OH		ERK1	ERK2			99.42%
Lidocaine (Standard)	ERK					99.85%
Tizaterkib			ERK2, IC₅₀: 0.6 nM			99.31%
CC-90003		ERK1	ERK2			99.71%
DEL-22379			ERK2, IC₅₀: 0.5 μM			99.69%
Ravoxertinib hydrochloride		ERK1, IC₅₀: 6.1 nM	ERK2, IC₅₀: 3.1 nM			99.93%
Rineterkib		ERK1	ERK2			99.83%
ERK5-IN-1				ERK5, IC₅₀: 87 nM		99.33%
MAP855	ERK, EC₅₀: 5 nM					98.48%
JWG-071				ERK5, IC₅₀: 88 nM		99.15%
Methylnissolin		ERK1	ERK2			99.86%
XMD17-109				ERK5, IC₅₀: 162 nM		99.20%
KO-947		ERK1	ERK2			99.61%
CK2/ERK8-IN-1					ERK8, IC₅₀: 0.5 μM	≥99.0%
ERK5-IN-2				ERK5, IC₅₀: 0.82 μM ERK5 MEF2D, IC₅₀: 3 μM		98.96%
Mogrol		ERK1	ERK2			99.76%
CHPG	ERK					99.51%
Magnolin		ERK1, IC₅₀: 87 nM	ERK2, IC₅₀: 16.5 nM			99.98%
β-Neo-Endorphin		ERK1	ERK2			99.32%
BIX02188				ERK5, IC₅₀: 810 nM		99.85%
4-Methylbenzylidene camphor		ERK1	ERK2			99.87%
Corynoxeine		ERK1	ERK2			99.97%
HIOC	ERK					99.94%
ASN007 benzenesulfonate		ERK1	ERK2			99.72%
Sanggenon C	ERK					98.50%
ERK-IN-4			ERK2, Kd: 5 μM			99.61%
AT-533		ERK1	ERK2			98.86%
Myristicin	ERK					99.89%
Loureirin B	ERK					99.16%
Cearoin	ERK					≥98.0%
CKLF1-C27		ERK1	ERK2			98.46%
Methylthiouracil		ERK1	ERK2			≥98.0%
Longdaysin			ERK2, IC₅₀: 52 μM			99.83%
2,5-Dihydroxyacetophenone		ERK1	ERK2			99.89%
Enniatin B1	ERK					99.34%
BAY885				ERK5, IC₅₀: 35 nM		99.27%
Deltonin		ERK1	ERK2			99.94%
Anti-inflammatory agent 35	ERK					99.77%
Omtriptolide	ERK
[Tyr8] Bradykinin		ERK1	ERK2			99.61%
Lidocaine hydrochloride hydrate	ERK					99.90%
ML192		ERK1	ERK2
Isoprocurcumenol	ERK
EVT801	ERK, IC₅₀: 13 nM
SHR2415		ERK1, IC₅₀: 2.8 nM	ERK2, IC₅₀: 5.9 nM			98.63%
ERK1/2 inhibitor 9		ERK1	ERK2
Syk-IN-6		ERK1	ERK2
Hypothemycin		ERK1, Ki: 8.4 μM	ERK2, Ki: 2.4 μM			≥98.0%
ERK5-IN-5				ERK5		99.05%
PT-262	ERK					99.21%
Bohemine			ERK2, IC₅₀: 52 μM			98.93%
Sugiol		ERK1	ERK2			99.88%
ERK2 IN-1			ERK2, IC₅₀: 7 nM
ERK-IN-2			ERK2, IC₅₀: 1.8 nM
ERK5-IN-3				ERK5, IC₅₀: 6 ± 1 nM
Aloisine A		ERK1, IC₅₀: 18 μM	ERK2, IC₅₀: 22 μM
ZINC12409120	ERK, IC₅₀: 5 μM
ERK-IN-7		ERK1, IC₅₀: 5 nM	ERK2, IC₅₀: 7 nM
ERK1/2 inhibitor 13		ERK1, IC₅₀: 91.71 nM	ERK2, IC₅₀: 97.87 nM
ERK-IN-2 free base			ERK2, IC₅₀: 1.8 nM
DCZ19931		ERK1	ERK2
ERK-IN-8			ERK2, IC₅₀: ≤50 nM
MHJ-627				ERK5
ERK2 IN-5			ERK2, Ki: 86 nM
PPM-3				ERK5, IC₅₀: 62.4 ± 18. nM
Enniatin B	ERK					99.10%
ERK2-IN-4			ERK2, Ki: 0.006 μM
ERK2 allosteric-IN-1			ERK2, IC₅₀: 11 μM
CKLF1-C27 TFA		ERK1	ERK2
Enniatin A1	ERK
Anti-inflammatory agent 31		ERK1	ERK2
ERK1/2 inhibitor 10		ERK1, IC₅₀: 0.11 nM	ERK2, IC₅₀: 0.8 nM
Myristoyl-MEK1 Derived Peptide Inhibitor 1	ERK, IC₅₀: 13 μM (The in vivo inhibitory potency is determined in both PMA-treated NIH 3T3 cells and NGF-stimulated PC12 cells.)		ERK2, IC₅₀: 10 μM (The in vitro inhibitory potency of the peptides is measured based on their ability to inhibit MEK1-mediated phosphorylation of ERK2. )
CXJ-2	ERK
MK2-IN-5		ERK1	ERK2
Cudraflavone B	ERK
ERK5-IN-4				ERK5
Anticancer agent 231		ERK1	ERK2
ERK5-IN-6	ERK
Phenylhydroquinone		ERK1	ERK2
Tizaterkib (hexanedioic acid)			ERK2, IC₅₀: 0.6 nM
Methyl helicterate		ERK1	ERK2

Name
Email *

	Sorry, but the email address you supplied was invalid.

ERK

ERK

ERK Isoform Specific Products:

ERK Isoform Specific Products:

ERK Related Products (442)

Antibodies (22)

ERK Isoform Comparison

ERK Related Products (442):